Phase 2 Trial of SJ733, a Novel PfATP4 Inhibitor for Malaria

Pharmacology, Toxicology and Pharmaceutical Science

1. Tablet 100%
2. Clinical Trial 100%
3. Pharmacokinetics 100%
4. Methemoglobinemia 50%
5. Tolerability 50%
6. Pharmacodynamics 50%
7. Monotherapy 50%
8. Adverse Event 50%
9. Drug Interaction 50%
10. Anemia 50%
11. Toxicology 50%